want to know more?
+31 (0)20 303 1970

Cell Chemical Biology paper: Proteasome Activation by Small Molecules;

The use of chemical probe Me4BodipyFL-Ahx3Leu3VS for identification of novel proteasome activity- modulating compounds.

Read More

UbiQ is now looking for an early career Researcher to join our Drug Discovery team.

(NB: Closing date was 17 April 2017, position has been filled successfully)

Read More

Mercachem and UbiQ join forces to tackle SUMOylation.

Read More

In honor of Prof. Yoshinori Ohsumi being awarded the Nobel prize in Medicine for his discoveries of mechanisms for autophagy, UbiQ has developed the activity-based probe His6-3C-MAP1LC3a-Dha (UbiQ-158). 

Read More

We here present UbiQ-141 (Mca-KKVAPYPME-Dap(Dnp)–NH2), which is a fluorogenic proteasome activity assay reagent based on the LF-2 peptide sequence. The reagent can be used to study activating factors of proteasome activity.*

Read More

Our publication highlights newsletter serves to highlight some of the recent reported work in the Ubiquitin Proteasome Field.

Read More

structural biology of UPS enzymes

with activity-based probes

Read More

We proudly present our new and revolutionary activity-based probes for the E1-E2-E3 enzyme cascade. Our Triple E probes represent the first tools that allow the monitoring of full E1-E2-E3 cascade activity.

Read More

New DUB probes allow you to study DUBs that use S2 ubiquitin pocket binding to modulate DUB activity.

Read More

Recently we introduced a new type of quenched ubiquitin rhodamine110 assay reagent, Ub-Rh110MP (UbiQ-126). In this newsletter we present some performance data.

Read More

To identify DUB inhibition, a competitive DUB activity profiling was performed using UbiQ’s activity based DUB probes. 

Read More

Here we would like to make a plea for in-gel fluorescent scanning by using fluorescently labeled probes. A method with many advantages.

Read More

UbiQ is introducing a new type of ubiquitin-rhodamine110 DUB assay reagent that doubles the fluorescence intensity.

Read More

Tools to support a new frontier of ubiquitin signalling research.

UbiQ has developed new tools, on the interface of ubiquitylation and phosphorylation signalling.

Read More

UbiQ has developed PINK1/Parkin related phosphorylated ubiquitins in cooperation with Ubiquigent and MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.

Read More

UbiQ and Ubiquigent have entered into a collaboration to commercialise novel reagents addressing a new frontier of integrated ubiquitylation and phosphorylation research central to Parkinson's disease.

Read More

UbiQ and Neuroscience Campus Amsterdam join forces to develop treatments for Parkinson’s disease and other neurodegenerative illnesses.

Read More

Publication on active-site directed probes in JACS

On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. Reggy Ekkebus , Sander Izaak van Kasteren , Yogesh Kulath... 

Read More